Drug Profile
Research programme: antibody-drug conjugates - ADC Therapeutics/Cancer Research Technology/University of Copenhagen
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ADC Therapeutics; Cancer Research UK; University of Copenhagen
- Developer ADC Therapeutics; Cancer Research Technology; Cancer Research UK; University of Copenhagen
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer